Pharma "cannot fix" health inequalities on its own, global industry body declares
This article was originally published in Scrip
This week (20 - 22 September) in New York, while world leaders attend a UN high-level summit to help accelerate progress towards the Millennium Development Goals (MDGs), the body that represents the pharmaceutical industry around the world, the IFPMA, has reminded them that pharma does good deeds, too. However, some critics say the industry needs to do more.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.